Provided by Tiger Trade Technology Pte. Ltd.

Anixa Biosciences

3.70
-0.0500-1.33%
Post-market: 3.63-0.0741-2.00%19:41 EDT
Volume:339.20K
Turnover:1.27M
Market Cap:125.89M
PE:-12.19
High:3.89
Open:3.76
Low:3.60
Close:3.75
52wk High:5.46
52wk Low:2.32
Shares:34.02M
Float Shares:32.19M
Volume Ratio:0.95
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3035
EPS(LYR):-0.3367
ROE:-71.97%
ROA:-41.91%
PB:8.70
PE(LYR):-10.99

Loading ...

Anixa Biosciences CEO Amit Kumar Acquires 5,000 Common Shares for $17,300

Reuters
·
Jul 21

Insider Move: Anixa Biosciences Director Deepens Stake in the Company

TIPRANKS
·
Jul 21

Anixa Biosciences Director Lewis H. Titterton Jr Acquires 12,000 Common Shares Valued at $41,640

Reuters
·
Jul 21

3 Penny Stocks With Market Caps Over $100M To Consider

Simply Wall St.
·
Jul 20

Anixa Biosciences Director Lewis H. Titterton Jr Acquires $9,172 of Common Shares

Reuters
·
Jul 16

Anixa Biosciences Says Australia Accepts Patent for Breast Cancer Vaccine Technology

Reuters
·
Jul 14

Anixa Biosciences CEO Amit Kumar Buys $15,200 Common Shares

Reuters
·
Jul 13

Anixa Advances Ovarian Cancer CAR-T Trial to Highest Dose Cohort in Phase 1 Study

Reuters
·
Jul 06

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

THOMSON REUTERS
·
Jul 06

Anixa Biosciences - Five Patients Surpass One Year Survival with Durations up to 28 Months

THOMSON REUTERS
·
Jul 06

Anixa Biosciences - no Dose-limiting Toxicities Observed up to Prior Dose Level of 3x10⁶/kg CAR-T Cells

THOMSON REUTERS
·
Jul 06

Anixa Biosciences Coverage Assumed by D. Boral Capital at Buy

Dow Jones
·
Jul 01

Anixa Biosciences assumed with a Buy at D. Boral Capital

TIPRANKS
·
Jun 30

Anixa Biosciences granted first Korean patent for breast cancer vaccine

TIPRANKS
·
Jun 29

Anixa Biosciences - Granted First Korean Patent for Breast Cancer Vaccine Through 2040

THOMSON REUTERS
·
Jun 29

Anixa Biosciences reports results from two clinical-stage immunotherapy programs

TIPRANKS
·
Jun 26

Anixa Reports Phase 1 Breast Cancer Vaccine Data Showing Immune Responses in 74% of Participants

Reuters
·
Jun 26

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

THOMSON REUTERS
·
Jun 26

Penny Stocks To Watch For Growth In June 2026

Simply Wall St.
·
Jun 19

Anixa Biosciences director Lewis H. Titterton Jr buys $7,487 of common shares

Reuters
·
Jun 17